DR.HOTHA'S
LIFE SCIENCES LLC

WHITE PAPER | 2025

ICH & FDA APPROACH TO CRITICAL QUALITY ATTRIBUTES (CQA'S)

UNDERSTANDING CQA'S ACROSS MODALITIES: SMALL MOLECULES, ANTIBODY-DRUG CONJUGATES (ADC'S), & PEPTIDES

Kishore Hotha, PhD,MBA

The development of pharmaceutical products is a complex, highly regulated process that requires meticulous attention to detail to ensure the final product's safety, efficacy, and quality. Critical Quality Attributes (CQAs) are fundamental to this process, serving as benchmarks defining a drug product's quality. This white paper explores the concept of CQAs, their importance in drug development, and the methodologies used to identify, monitor, and control them throughout the product lifecycle. By understanding and effectively managing CQAs, pharmaceutical companies can enhance product quality, comply with regulatory requirements, and ultimately deliver safe and effective therapies to patients.

INTRODUCTION:

The pharmaceutical industry is tasked with developing drugs that are not only effective but also safe and consistent in quality. Regulatory agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and others have established stringent guidelines to ensure drug products meet these standards. Central to these guidelines is the concept of Critical Quality Attributes (CQAs), which are the physical, chemical, biological, or microbiological properties or characteristics that must be controlled within appropriate limits to ensure the desired product quality.This white paper aims to provide a comprehensive overview of CQAs in drug development, including their definition, significance, and the processes involved in their identification and control. It also highlights the role of CQAs in ensuring regulatory compliance and improving patient outcomes.

UNDERSTANDING CRITICAL QUALITY ATTRIBUTES (CQAS)

CQAs are the measurable properties of a drug product that directly or indirectly impact its safety, efficacy, and quality. These attributes are identified based on their potential to affect the product's performance and are monitored throughout the drug development lifecycle.

CATEGORIES OF CQAS

CQAs can be classified into several key categories:

Physical Properties:
Characteristics such as appearance, particle size, dissolution rate, and viscosity.

Chemical Properties:
Purity, potency, stability, and degradation byproducts.

Biological Properties:
Elements including biological activity, immunogenicity, and protein structure.

Microbiological Properties:
Aspects such as sterility, endotoxin levels, and microbial contamination (bioburden).

IMPORTANCE OF CQAS

CQAs are essential for:
Maintaining drug safety and efficacy.
Guiding the development and optimization of manufacturing processes.
Aiding in regulatory approvals by ensuring compliance with quality standards.
Supporting quality control and post-market monitoring efforts.

IDENTIFICATION OF CQA'S

RISK-BASED IDENTIFICATION APPROACH

The identification of CQAs follows a risk-based approach, as recommended by the International Council for Harmonisation (ICH) Q8(R2) guidelines. This process involves:

Understanding the Product:
Defining the Target Product Profile (TPP) and the Quality Target Product Profile (QTPP).

Assessing Risks:
Using risk evaluation methods such as Failure Mode and Effects Analysis (FMEA) to identify potential quality risks.

Prioritizing Attributes:
Ranking CQAs based on their significance to product safety, efficacy, and quality.

Role of Analytical Techniques:
Advanced analytical methodologies play a crucial role in characterizing and quantifying CQAs. Techniques such as high-performance liquid chromatography (HPLC), mass spectrometry (MS), and spectroscopy provide the necessary data to define acceptable quality ranges and establish product specifications.

IDENTIFICATION OF CQAS

PRODUCT UNDERSTANDING

Defining the target product profile (TPP) and quality target product profile (QTPP).

RISK ASSESSMENT

Identifying potential risks to product quality through tools such as Failure Mode and Effects Analysis (FMEA).

PRIORITIZATION

Ranking attributes based on their impact on safety, efficacy, and quality.

FDA'S STANCE ON CQA



FDA'S STANCE ON CQAS

The FDA considers CQAs essential characteristics of a drug product that must be controlled to ensure safety, efficacy, and quality. The FDA encourages pharmaceutical manufacturers to adopt a proactive, science-driven approach to understanding and managing CQAs rather than relying solely on end-product testing. This approach aligns with the FDA's broader initiative to modernize pharmaceutical manufacturing and promote Quality by Design (QbD) principles.

Key aspects of the FDA's stance on CQAs include:

Risk-Based Approach:

The FDA advocates for a risk-based approach to identifying and controlling CQAs, as outlined in the ICH Q8(R2) guideline.

Patient-Centric Focus:

CQAs should be linked to the drug's impact on patient safety and efficacy.

Lifecycle Management:

CQAs should be monitored and controlled throughout the product lifecycle, from development to post-market surveillance.

Continuous Improvement:

The FDA encourages manufacturers to continuously use data-driven insights to improve processes and product quality.

FDA'S MODERNIZATION EFFORTS AND CQAS

The FDA modernizes pharmaceutical manufacturing by promoting advanced technologies and methodologies to enhance CQA management. Key initiatives include:

Emerging Technology Program: This program encourages the adoption of innovative technologies, such as continuous manufacturing and artificial intelligence, to improve CQA monitoring and control.

21st Century Cures Act: Supports patient-focused drug development and underscores the importance of CQAs in ensuring product quality and regulatory compliance.

ICH GUIDANCE'S ON CQA'S

KEY FDA GUIDELINES AND FRAMEWORKS ADDRESSING CQAS

The U.S. Food and Drug Administration (FDA) has issued several guidelines and frameworks that emphasize the importance of CQAs in pharmaceutical development and manufacturing. These guidelines help ensure product quality, safety, and efficacy by providing a structured approach to identifying, monitoring, and controlling CQAs.



KEY FDA GUIDELINES AND FRAMEWORKS ADDRESSING CQAS

GUIDELINE	FOCUS	KEY POINTS
ICH Q8(R2): PHARMACEUTICAL DEVELOPMENT	Emphasizes identifying CQAs during pharmaceutical development.	- CQAs are derived from the Quality Target Product Profile (QTPP). - A risk assessment process links CQAs to Critical Process Parameters (CPPs). - Promotes the use of Quality by Design (QbD) to embed quality into product development.
ICH Q9: QUALITY RISK MANAGEMENT	Provides a framework for risk management in pharmaceutical development and manufacturing.	- Risk assessment tools (e.g., Failure Mode and Effects Analysis - FMEA) identify and prioritize CQAs. - Risks associated with CQAs must be mitigated through control strategies.
ICH Q10: PHARMACEUTICAL QUALITY SYSTEM	Establishes a comprehensive quality system to manage CQAs throughout the product lifecycle.	- CQAs should be continuously monitored and controlled. - Encourages continuous improvement to address variability in CQAs.
FDA GUIDANCE FOR INDUSTRY: PROCESS ANALYTICAL TECHNOLOGY (PAT)	Promotes real-time monitoring and control of CQAs in manufacturing.	- PAT facilitates real-time quality assurance, reducing reliance on end-product testing. - CQAs can be monitored using advanced analytical tools integrated into the process.

KEY FDA GUIDELINES AND FRAMEWORKS ADDRESSING CQAS

GUIDELINE	FOCUS	KEY POINTS
FDA GUIDANCE FOR INDUSTRY: QUALITY BY DESIGN FOR ANDAS	Applies QbD principles to the development of generic drugs (Abbreviated New Drug Applications - ANDAs).	- CQAs must be identified and controlled to ensure bioequivalence and therapeutic equivalence. - Risk assessment and control strategies are critical for generic drug development.
FDA GUIDANCE FOR INDUSTRY: ANALYTICAL PROCEDURES AND METHODS VALIDATION	Outlines the validation of analytical methods for measuring CQAs.	- Analytical methods must be validated for accuracy, precision, and reliability. - Method validation is essential for establishing specifications and acceptance criteria for CQAs.
FDA GUIDANCE FOR INDUSTRY: DEVELOPMENT AND SUBMISSION OF NEAR INFRARED ANALYTICAL PROCEDURES	Discusses the application of near-infrared (NIR) spectroscopy for monitoring CQAs.	- NIR spectroscopy offers a non-destructive, real-time monitoring method for CQAs such as moisture content and drug concentration.

CRITICAL QUALITY ATTRIBUTES (CQAS) FOR DRUG SUBSTANCE (ACTIVE PHARMACEUTICAL INGREDIENT, API) AND DRUG PRODUCT (FINAL FORMULATED PRODUCT).

CATEGORY	DRUG SUBSTANCE (API)	DRUG PRODUCT (FINAL FORMULATION)	ANTIBODY-DRUG CONJUGATES (ADCS)	PEPTIDES
DEFINITION	CQAs are the physical, chemical, biological, or microbiological properties of the API that must be controlled to ensure the quality of the drug substance.	CQAs are the properties of the final drug product that must be controlled to ensure its safety, efficacy, and quality.	CQAs are the properties of the ADC that must be controlled to ensure its safety, efficacy, and quality.	CQAs are the properties of the peptide that must be controlled to ensure its safety, efficacy, and quality.
PHYSICAL ATTRIBUTES	- Particle size distribution - Polymorphic form - Solubility - Density - Appearance (color, morphology)	- Appearance (color, shape, opacity) - Uniformity of dosage units - Dissolution rate - Viscosity (for liquids)	- Aggregation (e.g., monomer, dimer, or higher-order aggregates) - Particle size (for lyophilized ADCs) - Reconstitution time	- Aggregation (e.g., fibril formation) - Solubility - Appearance (color, clarity)
CHEMICAL ATTRIBUTES	- Purity (impurity profile) - Potency (assay) - Stability (degradation products) - Residual solvents - Water content	- Potency (assay) - Degradation products - pH - Excipient compatibility - Stability (shelf life)	- Drug-to-antibody ratio (DAR) - Free drug (unconjugated payload) - Linker stability - Oxidation/deamidation sites	- Purity (impurity profile) - Sequence integrity - Post-translational modifications (e.g., glycosylation) - Oxidation/deamidation

CRITICAL QUALITY ATTRIBUTES (CQAS) FOR DRUG SUBSTANCE (ACTIVE PHARMACEUTICAL INGREDIENT, API) AND DRUG PRODUCT (FINAL FORMULATED PRODUCT).

CATEGORY	DRUG SUBSTANCE (API)	DRUG PRODUCT (FINAL FORMULATION)	ANTIBODY-DRUG CONJUGATES (ADCS)	PEPTIDES
BIOLOGICAL ATTRIBUTES	- Bioburden (for sterile APIs) - Endotoxin levels - Microbial limits (for non-sterile APIs)	- Sterility (for injectables) - Endotoxin levels - Preservative effectiveness (if applicable)	- Biological activity (e.g., target binding, cytotoxicity) - Immunogenicity - Fc effector function	- Biological activity (e.g., receptor binding, enzymatic activity) - Immunogenicity
MICROBIOLOGICAL ATTRIBUTES	- Microbial contamination - Bioburden - Endotoxin levels (for parenteral APIs)	- Microbial limits (for non-sterile products) - Sterility (for sterile products) - Container closure integrity	- Sterility (for injectables) - Bioburden - Endotoxin levels	- Sterility (for injectables) - Bioburden - Endotoxin levels
FUNCTIONAL ATTRIBUTES	- Reactivity (for intermediates) - Specific optical rotation (for chiral compounds)	- Drug release profile - Disintegration time (for tablets) - Reconstitution time (for lyophilized products)	- Payload release kinetics - Target binding affinity - Stability in circulation	- Stability under physiological conditions - Half-life in circulation
KEY CONSIDERATIONS	- Impurity levels (e.g., genotoxic impurities) - Crystal form (polymorphism) - Residual solvents	- Dissolution rate (for solid oral dosage forms) - Uniformity of dosage units - Stability under storage conditions	- Drug-to-antibody ratio (DAR) - Aggregation levels - Free drug content	- Sequence integrity - Aggregation levels - Oxidation/deamidation sites

CONCLUSION

Critical Quality Attributes (CQAs) play a fundamental role in drug development, ensuring that pharmaceutical products adhere to the highest standards of safety, efficacy, and quality. By employing a risk-based approach, utilizing advanced analytical methods, and implementing frameworks like Quality by Design (QbD) and Process Analytical Technology (PAT), pharmaceutical companies can systematically manage CQAs and maintain product integrity.

As the pharmaceutical landscape continues to evolve, a proactive strategy for identifying, understanding, and controlling CQAs is crucial to navigating the complexities of modern drug development. The FDA strongly emphasizes the importance of CQAs in safeguarding product quality and patient safety. Adhering to regulatory guidelines such as ICH Q8(R2), Q9, and Q10, along with leveraging industry-recognized quality frameworks, enables manufacturers to establish robust quality control systems throughout the product lifecycle.

By focusing on risk assessment, patient-centered approaches, and continuous quality improvement, the FDA aims to strengthen public health through stringent quality standards. For pharmaceutical companies, aligning with these regulatory expectations is essential for securing approvals, maintaining compliance, and consistently delivering safe and effective therapies to patients.

Author Biography:

Kishore Hotha, PhD, MBA

President, DR.HOTHA'S Life Sciences LLC

With over 20 years of experience in the biotech, CDMO, and pharmaceutical industries, Dr. Kishore Hotha specializes in end-to-end CMC development operations. As the founder of Dr. Hotha's Life Sciences LLC, he provides strategic consulting in complex small molecules, ADCs, Oligonucleotides, and Peptides, supporting clients from discovery through regulatory submissions.

Dr. Hotha has led high-performing global teams, implemented scalable systems across international sites, and managed over 80 client projects. His contributions include supporting 90+ regulatory submissions (INDs, NDAs, ANDAs) and delivering 45+ successful commercialization. Known for his ability to navigate complex CMC challenges, he has transformed strategies to meet fast-to-market demands while enhancing R&D capabilities.

A prolific author with over 80 publications, Dr. Hotha also serves on editorial boards and frequently speaks at international conferences. His PhD in Analytical Chemistry and MBA in Project Management empower him to deliver innovative, results-driven solutions that advance drug development and commercialization.

Mobile +1-978-501-4938
email: contact@drhothas.com

Visit us: drhothas.com

ABOUT US

Dr. Hotha’s Life Sciences LLC is a Global biotech consulting firm specializing in comprehensive pharmaceutical and life sciences solutions. With more than two decades of expertise, we partner with clients to guide them through the entire drug development lifecycle—from early discovery to market entry. Our proficiency spans therapeutic areas, focusing on small and large molecules, ADCs, Oligonucleotides, and Peptides, ensuring successful outcomes for drug substances and products.

OUR MISSION

At Dr. Hotha’s Life Sciences LLC, we transform complex challenges into clear, actionable strategies. Our mission is to simplify CMC drug development by providing bespoke solutions for regulatory submissions, including INDs, NDAs, and ANDAs. We are dedicated to delivering fast-to-clinic and fast-to-market strategies that maximize quality, accelerate project timelines, and meet stringent regulatory standards.

Complexity to Clarity Together

With a strong focus on early-phase to late-phase projects, Drug substances, and Drug products, we offer end-to-end consulting services that guide our clients through every development phase—from initial discovery to regulatory submission.

Our Approach:

Partner: We believe in solid collaborations. By partnering closely with our clients, we build tailored strategies that align with your unique goals and challenges.

Plan: We provide strategic planning that encompasses the entire development lifecycle. Whether navigating complex regulatory environments or optimizing lab operations, we ensure that your project is equipped for success.

Prosper: With our expertise and guidance, you can bring life-saving therapies to market faster, achieving sustainable growth and long-term success.

Mobile +1-978-501-4938
email: contact@drhothas.com

Visit us: drhothas.com